ABSTRACT
There is an urgent need for new antibiotics against Gram-negative pathogens that are resistant to carbapenem and third-generation cephalosporins, against which antibiotics of last resort have lost most of their efficacy. Here we describe a class of synthetic antibiotics inspired by scaffolds derived from natural products. These chimeric antibiotics contain a ß-hairpin peptide macrocycle linked to the macrocycle found in the polymyxin and colistin family of natural products. They are bactericidal and have a mechanism of action that involves binding to both lipopolysaccharide and the main component (BamA) of the ß-barrel folding complex (BAM) that is required for the folding and insertion of ß-barrel proteins into the outer membrane of Gram-negative bacteria. Extensively optimized derivatives show potent activity against multidrug-resistant pathogens, including all of the Gram-negative members of the ESKAPE pathogens1. These derivatives also show favourable drug properties and overcome colistin resistance, both in vitro and in vivo. The lead candidate is currently in preclinical toxicology studies that-if successful-will allow progress into clinical studies that have the potential to address life-threatening infections by the Gram-negative pathogens, and thus to resolve a considerable unmet medical need.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Gram-Negative Bacteria/drug effects , Peptidomimetics/chemistry , Peptidomimetics/pharmacology , Animals , Anti-Bacterial Agents/adverse effects , Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/genetics , Biological Products/chemistry , Drug Discovery , Drug Resistance, Microbial/drug effects , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Fluorescence , Gram-Negative Bacteria/genetics , Gram-Negative Bacteria/pathogenicity , Humans , Lipopolysaccharides/chemistry , Macrocyclic Compounds/adverse effects , Macrocyclic Compounds/chemistry , Macrocyclic Compounds/pharmacology , Male , Mice , Microbial Sensitivity Tests , Microbial Viability/drug effects , Microscopy, Electron, Transmission , Models, Molecular , Mutation , Peptidomimetics/adverse effects , Photoaffinity LabelsABSTRACT
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
ABSTRACT
The rise of antimicrobial resistance poses a substantial threat to our health system, and, hence, development of drugs against novel targets is urgently needed. The natural peptide thanatin kills Gram-negative bacteria by targeting proteins of the lipopolysaccharide transport (Lpt) machinery. Using the thanatin scaffold together with phenotypic medicinal chemistry, structural data, and a target-focused approach, we developed antimicrobial peptides with drug-like properties. They exhibit potent activity against Enterobacteriaceae both in vitro and in vivo while eliciting low frequencies of resistance. We show that the peptides bind LptA of both wild-type and thanatin-resistant Escherichia coli and Klebsiella pneumoniae strains with low-nanomolar affinities. Mode of action studies revealed that the antimicrobial activity involves the specific disruption of the Lpt periplasmic protein bridge.
Subject(s)
Escherichia coli Proteins , Peptidomimetics , Enterobacteriaceae , Lipopolysaccharides , Peptidomimetics/pharmacology , Escherichia coli , Anti-Bacterial Agents/pharmacology , Carrier ProteinsABSTRACT
This review describes a selection of macrocyclic natural products and structurally modified analogs containing peptidic and non-peptidic elements as structural features that potentially modulate cellular permeability. Examples range from exclusively peptidic structures like cyclosporin A or phepropeptins to compounds with mostly non-peptidic character, such as telomestatin or largazole. Furthermore, semisynthetic approaches and synthesis platforms to generate general and focused libraries of compounds at the interface of cyclic peptides and non-peptidic macrocycles are discussed.
Subject(s)
Macrocyclic Compounds/chemistry , Peptides, Cyclic/chemistry , Biological Products , Cyclization , Depsipeptides/chemistry , Depsipeptides/metabolism , Humans , Lactones/chemistry , Lactones/metabolism , Macrocyclic Compounds/chemical synthesis , Oxazoles/chemistry , Oxazoles/metabolism , Peptide Library , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/metabolism , Permeability , Protein Conformation , Spiro Compounds/chemistry , Spiro Compounds/metabolism , Streptogramins/chemistry , Streptogramins/metabolism , Thiazoles/chemistry , Thiazoles/metabolismABSTRACT
Fluorometric imaging plate reader (FLIPR) membrane potential dyes (FMP-Red-Dye and FMP-Blue-Dye) were evaluated for the detection of compounds acting either as positive allosteric modulators or agonists on the GABA(A) receptor (GABA(A)R). A stable HEK293 cell line with constitutive expression of the rat GABA(A)R alpha1, beta2, and gamma2 genes was used to establish a functional high-throughput screening (HTS) assay based on measurement of the membrane potential change in living cells. The assay was validated with the FLIPR technology for identification of agonists and positive allosteric modulators using GABA and diazepam as model compounds. The FMP-Red-Dye showed better performance than the FMP-Blue-Dye, and the effects induced by GABA and diazepam were comparable to electrophysiology data. Subsequently, the assay was also validated with an ultra-HTS approach known as microarrayed compound screening (microARCS). The LOPAC library was used in a test screen for an initial assessment of the technology. Finally, the FLIPR and microARCS technologies were tested with a larger screening campaign. A focused library of 3520 putative positive modulators was tested with the FLIPR assay, and a diverse subset of 84,480 compounds was selected for screening with the microARCS technology. All hits were subjected to verification using the FLIPR technology, and confirmed hits were subsequently evaluated by EC50 determination. Finally, selected hits were further confirmed with electrophysiology testing.
Subject(s)
Biological Assay/methods , Coloring Agents/analysis , Drug Evaluation, Preclinical/methods , Membrane Potentials/physiology , Membrane Transport Modulators/analysis , Receptors, GABA-A/metabolism , Animals , Cell Line , Diazepam/pharmacology , Dose-Response Relationship, Drug , Electrophysiology , Fluorescence , Humans , Membrane Potentials/drug effects , Pertussis Toxin/pharmacology , Rats , Reproducibility of Results , gamma-Aminobutyric Acid/pharmacologyABSTRACT
This review describes recent developments in the evolutionary process of microarrayed compound screening (microARCS to become a robust and efficient ultra-high-throughput screening technology. Improvements in compound spotting (including new quality-control methods), gel casting and imaging, together with software capable of automatic analysis and deconvolution of images, have helped to streamline the screening process. A variety of screening projects using cell-based and non-cell-based approaches have been successfully concluded using microARCS. Comparison of hits derived from standard microtitre-plate-based screening and from microARCS reveals excellent overlap. Furthermore, there seems to be no bias towards finding compounds within a particular range of logP values, even though compounds are solubilized from a dry state during the course of the assay.
Subject(s)
Chemistry, Pharmaceutical/methods , Drug Evaluation, Preclinical/methods , Pharmaceutical Preparations/chemistry , Biological Assay/methods , Gels , Miniaturization/instrumentation , Miniaturization/methods , Software , Structure-Activity RelationshipABSTRACT
A cell-based assay using homogeneous time-resolved fluorescence has been developed for high throughput screening of putative beta-amyloid (Abeta)production inhibitors. In this assay, total Abeta is detected by simply adding two commercially available antibody complexes. The first was a biotinylated monoclonal antibody (4G8), specifically recognizing an epitope comprising the residues 17-24 of the Abetapeptide, complexed with europium cryptate-streptavidin conjugate. The second was a polyclonal antibody (BioS-N), raised against the N-terminus of the Abeta peptide, complexed with an allophycocyanin-anti rabbit antibody conjugate. Binding of the two complexes to the Abeta peptide brought europium cryptate (fluorescence donor) and allophycocyanin (fluorescence acceptor) into close proximity, consequently a fluorescent resonance energy transfer signal was produced upon excitation at 337 nm. The resulting fluorescence signal (665 nm) was then detected using a Discovery or a ViewLux reader. Detection of Abeta by the proposed method is possible at concentrations of approximately 1 nM. The method was employed for the detection of Abeta secreted from a stable transfected human neuroglioma cell line (H4) overexpressing a mutated form of the human amyloid precursor protein (APP695NL) and developed for robotic automation. At optimized conditions, signal-to-background ratios exceeding 5 and Z' factors around 0.7 were achieved in a 384-well format. High throughput screening of 56,913 potential Abeta production inhibitors led to identification of new non-cytotoxic and cell permeable compounds with potencies in the submicromolar range.
Subject(s)
Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/metabolism , Antibodies, Monoclonal , Cells, Cultured , Chromatography, Liquid , Drug Evaluation, Preclinical , Enzyme-Linked Immunosorbent Assay , Fluorescent Dyes , Humans , Immunoassay , Mass SpectrometryABSTRACT
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of (14)C-labeled imatinib mesylate. Biological fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatography with off-line microplate solid scintillation counting and characterized by liquid chromatography-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (t(max) 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approximately 65 and 9% of total systemic exposure [AUC(0-24 h) (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, respectively. The remaining proportion corresponded mainly to oxidized derivatives of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approximately 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, respectively.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Piperazines/pharmacokinetics , Protein Kinase Inhibitors/pharmacokinetics , Pyrimidines/pharmacokinetics , Adult , Antineoplastic Agents/blood , Antineoplastic Agents/urine , Benzamides , Biotransformation , Chromatography, Liquid , Cytochrome P-450 CYP2D6/genetics , Feces/chemistry , Genotype , Humans , Imatinib Mesylate , Male , Mass Spectrometry , Middle Aged , Piperazines/blood , Piperazines/urine , Protein Kinase Inhibitors/blood , Protein Kinase Inhibitors/urine , Pyrimidines/blood , Pyrimidines/urineABSTRACT
Ochratoxins are mycotoxins released by moulds on grain, peanuts and vegetables. Toxicological investigations have shown that ochratoxin A displays nephrotoxic, genotoxic, teratogenic, cancerogenic and immunosuppressive effects. Increased blood levels observed in humans would seem to suggest a link to a kidney desease (Balcan Endemic Nephropaty) frequently observed in the Balkan countries. The adverse effects of ochratoxin A are mainly associated with its impact on phenylalanine-metabolizing enzymes. Based on the three-dimensional structure of phenylalanine-t-RNA-synthetase, its interactions with ochratoxins are analyzed as well as with Aspartam. In animal models, Aspartam has been shown to almost fully prevent toxic effects of ochratoxin A. The topology of the binding site of phenylalanine-t-RNA-synthetase would seem to be favorable towards a few affinity-enhancing modifications of the Aspartame molecule. A known molecular mechanism is a prerequisite for a systematic search of antagonizing substances for toxins. Based on a receptor structure, binding properties of such drugs can be identified and optimized using computer-aided drug design. Susequently, only the most potent candidate structures must be subjected to a determination of their biological activity, which can lead to a significant reduction of substances to be tested in vivo. Such experiments are particularly stressful as the animals must be intoxicated beforehand. The extent of an antagonistic impact on humans suffering from a chronical ochratoxin A intoxication must be subject of clinical studies.